Skip to main content

Table 1 The details of FIGHT and LIVE trials

From: Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE

  FIGHT LIVE
Liraglutide (N = 154) Placebo (N = 146) Liraglutide (N = 122) Placebo (N = 119)
Genaral data
 Age 62 (52–68) 61 (51–67) 65 ± 9.2 65 ± 10.7
 Male 123 (80%) 113 (77%) 109 (89%) 106 (89%)
 BMI (kg/m2) 31 (26–36) 33 (25–38) 28.0 ± 3.8 29.8 ± 4.6
Functional measures
 6MWT (m) 234 (143–313) 212 (141–311) 453 ± 104 441 ± 122
NYHA
 I 4 (3%) 8 (5%) 36 (30%) 35 (29%)
 II 49 (32%) 36 (25%) 65 (53%) 64 (54%)
 III 93 (60%) 96 (66%) 17 (14%) 16 (13%)
 IV 8 (5%) 6 (4%) 4 (3%) 4 (3%)
Physical examination
 SBP 108 (99–120) 108 (99–118) 128 ± 20 127 ± 18
 HR 75 (68–85) 76 (68–88) 67 ± 10 67 ± 11
Medical history
 T2DM 91 (59%) 87 (60%) 39 (32%) 35 (29%)
 AF 74 (48%) 70 (48%) 34 (28%) 34 (29%)
 Ischemic heart disease 133 (86%) 113 (77%) 72 (59%) 73 (61%)
Laboratory measures
 NT-proBNP (pg/mL) 1936 (1075–4231) 2083 (1020–4333) 413 (208–926) 388 (153–880)
 HbA1c (%) 6.6 (6.6–7.6) 6.7 (5.9–7.9) 5.9 ± 0.7 6.0 ± 0.8
Echocardiographic data
 LVEF (%) 25 (20–33) 25 (19–32) 33.7 ± 7.6 35.4 ± 9.4
 LVESV (mL) 104 (78–130) 100 (80–1330 111 ± 60 109 ± 78
 LVEDV (mL) 140 (112–173) 137 (115–174) 163 ± 71 165 ± 111
 E/e' 22 (17–28) 23 (18–30) 12.6 ± 6.0 11.7 ± 5.5
Heart failure medications
 ACEI/ARB 112 (73%) 104 (71%) 118 (97%) 115 (97%)
 β-Blocker 143 (93%) 139 (95%) 113 (93%) 108 (91%)
 Aldosterone recepter antagonist 88 (57%) 89 (61%) 59 (48%) 54 (45%)
 Loop diuretic 151 (98%) 146 (100%) 90 (74%) 90 (76%)
 Lipid-lowering agent 110 (71%) 110 (75%) 96 (79%) 92 (77%)
Treatmen effect
 LVEF  − 0.1 (− 2.3–2.1)  − 0.8 (− 2.1–0.5)
 LVESV 5 (− 2.6–12.7) 2.6 (− 1.2–6.4)
 LVEDV 6.7 (− 2.6–16) 3.4 (− 2.3–9.2)
 6MWT 5 (− 29–39) 24 (2–47)
 NT-proBNP (pg/mL)  − 155 (− 1368–1058) − 140 (− 317–37)
 HbA1c (%)  − 0.33 (− 0.67–0)  − 0.4 (− 0.5– − 0.3)
 HR  − 1.6 (− 4.8–1.6) 7 (5–9)
  1. FIGHT Functional Impact of GLP-1 for Heart Failure Treatmen, LIVE Effect of Liraglutide on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes, BMI body mass index, 6MWT 6-min walk test, NYHA New York Heart Association, SBP systolic blood pressure, HR heart rate, T2DM type 2 diabetes mellitus, AF atrial fibrillation, NT-proBNP N-terminal pro-B-type natriuretic peptide, HbA1 chemoglobin A1c, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume index, LVEDV left ventricular end-diastolic volume index, E/e' ratio of early mitral inflow velocity to early diastolic medial mitral annular velocity, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker